Host Cell Proteins in Biologics Manufacturing: The Good, the Bad, and the Ugly

Significant progress in the manufacturing of biopharmaceuticals has been made by increasing the overall titers in the USP (upstream processing) titers without raising the cost of the USP. In addition, the development of platform processes led to a higher process robustness. Despite or even due to th...

Descripción completa

Detalles Bibliográficos
Autores principales: Kornecki, Martin, Mestmäcker, Fabian, Zobel-Roos, Steffen, Heikaus de Figueiredo, Laura, Schlüter, Hartmut, Strube, Jochen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698861/
https://www.ncbi.nlm.nih.gov/pubmed/31548528
http://dx.doi.org/10.3390/antib6030013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698861/
https://www.ncbi.nlm.nih.gov/pubmed/31548528
http://dx.doi.org/10.3390/antib6030013

Ejemplares similares